These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. Hao X, Feng R, Bi Y, Liu Y, Li C, Lu T, Tian Y. J Neurosurg Pediatr; 2019 Jan 01; 23(1):48-53. PubMed ID: 30265230 [Abstract] [Full Text] [Related]
5. Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of Langerhans cell histiocytosis. Perić P, Antić B, Knezević-Usaj S, Radić-Tasić O, Radovinović-Tasić S, Vasić-Vilić J, Sekulović L, Tarabar O, Tukić L, Jovandić S, Magić Z. Vojnosanit Pregl; 2016 Jan 01; 73(1):83-7. PubMed ID: 26964390 [Abstract] [Full Text] [Related]
6. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. Haroche J, Cohen-Aubart F, Charlotte F, Maksud P, Grenier PA, Cluzel P, Mathian A, Emile JF, Amoura Z. Expert Rev Clin Immunol; 2015 Jan 01; 11(9):1033-42. PubMed ID: 26197238 [Abstract] [Full Text] [Related]
8. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both BRAF and KRAS mutations. Nordmann TM, Juengling FD, Recher M, Berger CT, Kalbermatten D, Wicki A, Paasinen-Sohns A, Cathomas G, Tzankov A, Daikeler T. Blood; 2017 Feb 16; 129(7):879-882. PubMed ID: 27940476 [Abstract] [Full Text] [Related]
11. Erdheim-Chester disease with bilateral orbital masses and multi-systemic symptoms: two case reports. Qiao J, Ma R, Peng X, He W. World J Surg Oncol; 2023 Jul 31; 21(1):233. PubMed ID: 37525276 [Abstract] [Full Text] [Related]
12. Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report. Tamura S, Kawamoto K, Miyoshi H, Suzuki T, Katagiri T, Kasami T, Nemoto H, Miyakoshi S, Kobayashi H, Shibasaki Y, Masuko M, Takeuchi K, Ohshima K, Sone H, Takizawa J. J Clin Exp Hematop; 2018 Dec 13; 58(4):161-165. PubMed ID: 30305475 [Abstract] [Full Text] [Related]
13. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation. Nikpanah M, Kim L, Mirmomen SM, Symons R, Papageorgiou I, Gahl WA, O'Brien K, Estrada-Veras JI, Malayeri AA. Eur Radiol; 2018 Sep 13; 28(9):3751-3759. PubMed ID: 29556768 [Abstract] [Full Text] [Related]
14. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation. Johnson WT, Patel P, Hernandez A, Grandinetti LM, Huen AC, Marks S, Ho J, Monaco SE, Jaffe R, Picarsic J. J Cutan Pathol; 2016 Mar 13; 43(3):270-5. PubMed ID: 26454140 [Abstract] [Full Text] [Related]
15. An effective treatment in Erdheim Chester disease: vemurafenib: a case report. Bozan E, Darçın T, Yaman S, Yiğenoğlu TN, Kızıl Çakar M, Dal MS, Altuntaş F. J Med Case Rep; 2023 Oct 12; 17(1):426. PubMed ID: 37821987 [Abstract] [Full Text] [Related]